Effects of Pioglitazone in Congenital Adrenal Hyperplasia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00151710 |
Recruitment Status :
Completed
First Posted : September 9, 2005
Last Update Posted : March 1, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Congenital Adrenal Hyperplasia | Drug: Pioglitazone | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double |
Official Title: | Effects of Pioglitazone in Glucocorticoid-Induced Insulin Resistance. Studies in Congenital Adrenal Hyperplasia. |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- biochemical and genetically proven congenital adrenal hyperplasia
- stable corticosteroid replacement for 3 months
Exclusion Criteria:
- age < 18 years
- inability to give informed consent
- significant cardiovascular disease, defined as myocardial infarction or stroke, six months preceding the study
- significant renal disease, GFR < 30 ml/min
- significant liver disease, defined as more than 3 times upper limit of normal values of alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
- pregnancy
- mental disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00151710
Netherlands | |
Radboud University Nijmegen Medical Centre | |
Nijmegen, Gelderland, Netherlands, 6500 HB |
Principal Investigator: | Cornelis J Tack, MD, PhD | Radboud University Medical Center |
ClinicalTrials.gov Identifier: | NCT00151710 |
Other Study ID Numbers: |
H6E-UT-O013 |
First Posted: | September 9, 2005 Key Record Dates |
Last Update Posted: | March 1, 2007 |
Last Verified: | February 2007 |
Adrenal Hyperplasia, Congenital Adrenogenital Syndrome Adrenocortical Hyperfunction Hyperplasia Pathologic Processes Disorders of Sex Development Urogenital Abnormalities Congenital Abnormalities Genetic Diseases, Inborn |
Steroid Metabolism, Inborn Errors Metabolism, Inborn Errors Metabolic Diseases Adrenal Gland Diseases Endocrine System Diseases Gonadal Disorders Pioglitazone Hypoglycemic Agents Physiological Effects of Drugs |